a year ago

Newcells Biotech Secures £2.35 Million to Advance 3D Drug Testing

  • Newcells Biotech, a UK-based company specializing in 3D models for pharmaceutical drug testing, has raised £2.35 million in funding, bringing the total raised to £12 million

  • The funding round saw participation from North East Venture Fund, European Regional Development Fund, Mercia Ventures, Mercia's own funds, and Northstar Ventures

  • The company plans to use the funds to boost its growth and establish itself as a leading player in its field

  • Newcells offers 3D models of the retina, kidney, and lung, and provides customized testing services to pharmaceutical companies

  • The company's non-animal testing methods are gaining traction due to recent changes in FDA guidance.

      • ProblemHealthcare

      "Pharmaceutical companies struggle with expensive and time-consuming animal testing to assess drug efficacy and safety."

      Solution

      "Newcells Biotech provides 3D models that mimic human organs, allowing pharmaceutical companies to test drugs in a more efficient and ethical way, reducing reliance on animal testing."

      Covered on